Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

NAYRAC

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Journal of Virology|September 9, 2024
The combination of three CD4-induced antibodies targeting highly conserved Env regions with a small CD4-mimetic achieves potent ADCC activityLorie Marchitto, Jonathan Richard, Jérémie Prévost, et al.
Cell Reports. Medicine|May 10, 2021
Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onsetSai Priya Anand, Jérémie Prévost, Manon Nayrac, et al.
Biorxiv : the Preprint Server for Biology|January 4, 2022
Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimenManon Nayrac, Mathieu Dubé, Gérémy Sannier, et al.
Cell Reports|June 22, 2022
Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimenManon Nayrac, Mathieu Dubé, Gérémy Sannier, et al.
Cell Host & Microbe|June 16, 2021
A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responsesAlexandra Tauzin, Manon Nayrac, Mehdi Benlarbi, et al.
Cell Host & Microbe|December 26, 2021
Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between dosesAlexandra Tauzin, Shang Yu Gong, Guillaume Beaudoin-Bussières, et al.
Biorxiv : the Preprint Server for Biology|March 24, 2021
A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responsesAlexandra Tauzin, Manon Nayrac, Mehdi Benlarbi, et al.
Cell Reports. Medicine|March 2, 2023
A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4<sup>+</sup> T cell profileGérémy Sannier, Alexandre Nicolas, Mathieu Dubé, et al.
Science Advances|November 26, 2021
Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortalityElsa Brunet-Ratnasingham, Sai Priya Anand, Pierre Gantner, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Journal of Virology|September 9, 2024
The combination of three CD4-induced antibodies targeting highly conserved Env regions with a small CD4-mimetic achieves potent ADCC activityLorie Marchitto, Jonathan Richard, Jérémie Prévost, et al.
Cell Reports. Medicine|May 10, 2021
Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onsetSai Priya Anand, Jérémie Prévost, Manon Nayrac, et al.
Biorxiv : the Preprint Server for Biology|January 4, 2022
Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimenManon Nayrac, Mathieu Dubé, Gérémy Sannier, et al.
Cell Reports|June 22, 2022
Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimenManon Nayrac, Mathieu Dubé, Gérémy Sannier, et al.
Cell Host & Microbe|June 16, 2021
A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responsesAlexandra Tauzin, Manon Nayrac, Mehdi Benlarbi, et al.
Cell Host & Microbe|December 26, 2021
Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between dosesAlexandra Tauzin, Shang Yu Gong, Guillaume Beaudoin-Bussières, et al.
Biorxiv : the Preprint Server for Biology|March 24, 2021
A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responsesAlexandra Tauzin, Manon Nayrac, Mehdi Benlarbi, et al.
Cell Reports. Medicine|March 2, 2023
A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4<sup>+</sup> T cell profileGérémy Sannier, Alexandre Nicolas, Mathieu Dubé, et al.
Science Advances|November 26, 2021
Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortalityElsa Brunet-Ratnasingham, Sai Priya Anand, Pierre Gantner, et al.
Pageof 4